Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.
The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to help prevent future heart attacks or strokes through home-based digital solutions.
The focus is on the major risk factors, non-invasive ways of lipid testing and blood pressure management using software as a medical device (SaMD).
Applications are open to health-tech start-up founders, researchers, and technologists working on innovative solutions to enable system-wide change in cardiovascular disease (CVD) patient care pathways.
The Novartis Biome UK is leading this first of its kind investor partnership, combining its patient pathway knowledge with Medtronic’s experience as the global leader in healthcare technology.
RYSE Asset Management, the specialist healthcare investor, will provide up to £3 million ($3.6 million) in investment and the CW Innovation program – a collaboration between Chelsea and Westminster Hospital NHS Foundation Trust and CW+ – will work to establish a real-world clinical evaluation for selected solutions.
The post Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.